Bruce Booth sold $35M of KYMR
director at Kymera Therapeutics, Inc.. 285,684 shares at an average of $121.86, traded Jun 25, 2026, filed Jun 25, 2026.
Score components
- +15RoleDirector
- +25Trade size$34.8M at market
- 0Share of holdings soldSold 9.2% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001451612-26-000016, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -37,179 | $119.71 | $4.5M | 3,075,906 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -112,299 | $120.66 | $14M | 2,963,607 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -40,774 | $121.38 | $4.9M | 2,922,833 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -4,977 | $122.67 | $611k | 2,917,856 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -10,860 | $123.62 | $1.3M | 2,906,996 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -11,711 | $124.61 | $1.5M | 2,895,285 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -3,716 | $125.82 | $468k | 2,891,569 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,609 | $126.71 | $204k | 2,889,960 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -25,075 | $127.37 | $3.2M | 2,864,885 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2,197 | $128.69 | $283k | 2,862,688 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -337 | $129.61 | $44k | 2,862,351 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -5,144 | $119.71 | $616k | 559,524 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -15,660 | $120.66 | $1.9M | 543,864 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -5,689 | $121.38 | $691k | 538,175 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -698 | $122.67 | $86k | 537,477 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,517 | $123.62 | $188k | 535,960 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,639 | $124.61 | $204k | 534,321 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -522 | $125.82 | $66k | 533,799 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -223 | $126.71 | $28k | 533,576 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -3,507 | $127.37 | $447k | 530,069 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -305 | $128.69 | $39k | 529,764 | Jun 25, 2026 |
| Jun 25, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -46 | $129.61 | $5,962 | 529,718 | Jun 25, 2026 |
Related signals
Other insiders at Kymera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $3.4M 30,000 shares | -4% | |
| 41Moderate | KYMRsell Kymera Therapeutics, Inc. | Brian Adams Chief Legal Officer | $744k 6,371 shares | -11% | |
| 40Moderate | Kymera Therapeutics, Inc. | Bruce Booth director | $56M 513,245 shares | -18% | |
| 35Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $3.4M 31,283 shares | -1% | |
| 75Notable | Kymera Therapeutics, Inc. | Bvf Partners L P/il director, other | $174M 1,630,658 shares | -58% | |
| 40Moderate | Kymera Therapeutics, Inc. | Bruce Booth director | $44M 398,765 shares | -12% | |
| 14Weak | Kymera Therapeutics, Inc. | Noah Goodman Chief Business Officer | $570k 5,000 shares | -9% | |
| 40Moderate | Kymera Therapeutics, Inc. | Bruce Booth director | $45M 478,198 shares | -4073% | |
| 35Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $3.3M 31,798 shares | -1% | |
| 8Weak | Kymera Therapeutics, Inc. | Noah Goodman Chief Business Officer | $248k 2,500 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.